Literature DB >> 24574636

Membranous nephropathy superimposed on Churg-Strauss syndrome.

R Ram1, C Shyam Sunder Rao1, G Swarnalatha1, K Sireesha2, H R Madhuri2, L Rajasekhar2, K V Dakshinamurty1.   

Abstract

The association of membranous nephropathy with Churg-Strauss syndrome is not widely reported. We present a patient with myeloperioxidase-perinuclear antineutrophilic cytoplasmic antibody (MPO-pANCA)-positive necrotizing and crescentic glomerulonephritis who later developed membranous nephropathy.

Entities:  

Keywords:  Churg-Strauss syndrome; MPO; membranous nephropathy; pANCA

Year:  2014        PMID: 24574636      PMCID: PMC3927196          DOI: 10.4103/0971-4065.125132

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


Introduction

The association of membranous nephropathy with Churg-Strauss syndrome is not widely reported. We report a patient who was first diagnosed as having Churg-Strauss syndrome and after 6 years, upon evaluation for a new onset nephrotic syndrome, the patient was found to have membranous nephropathy.

Case Report

A 37-year-old man was treated for Churg-Strauss syndrome 6 years back. It was diagnosed when he had history of problems such as breathlessness, wheezing, sticky sputum, weight loss, and myalgias. He also had history of cough and expectoration. He had these symptoms for 10 years before that presentation. He had joint pains, particularly metacarpophalangeal, interphalangeal, and wrist joints. He complained of subcutaneous nodules over upper and lower limbs. He also had rhinorrhea and later he was found to have nasal polyp. He had no symptoms such as abdominal pain, diarrhea, gastrointestinal bleeding, weakness of limbs and symptoms related to stroke, ophthalmologic involvement, and cardiac failure. His previous investigations are reported in Table 1.
Table 1

Investigations

Investigations At present, he complained of facial puffiness which gradually progressed to entire body. There was no antecedent history of fever or skin disease. There was history of increased frothiness of urine. There was no history of oliguria and hematuria. He also complained of breathlessness, wheezing, cough, and expectoration, particularly in the morning. His blood pressure was 160/90 mm of Hg. The present investigations are reported in Table 1. On light microscopy, kidney biopsy revealed the following: 15 glomeruli, 3 sclerosed, and 5 showed focal necrosis and cellular crescents. Glomeruli showed diffuse thickening of glomerular basement membrane [Figure 1]. Spikes were present. Tubules, vessels, and interstitium were unremarkable. Immunofluorescence assay revealed: IgG 3+, IgM 1+, κ 1+, and λ 1 + in glomeruli. Electron microscopy was not performed. HbsAg Hepatitis B surface antigen and anti-HCV anti- hepatitis C virus antibodies were negative. Human immunodeficiency virus was non-reactive. Cytoplasmic antineutrophilic cytoplasmic antibody cANCA, anti nuclear antibody ANA, and anti double stranded DNA antibody anti-dsDNA were negative. Complements were within normal limits.
Figure 1

Glomerulus showing thickening of glomerular basement membrane with a cellular crescent (PAS Periodic acid stain, × 100)

Glomerulus showing thickening of glomerular basement membrane with a cellular crescent (PAS Periodic acid stain, × 100) At first presentation, he was treated with methylprednisolone 15 mg/kg/d intravenous for 3 days followed by oral prednisolone 0.5 mg/kg/d for 3 months and was tapered to 10 mg/day by 6 months. He was continued on that dose, till the present complaints. At present, he received intravenous methylprednisolone 15 mg/kg/d intravenous for 3 days followed by intravenous cyclophosphamide 500 mg and oral prednisolone 0.5 mg/kg/d. He also received monthly doses of intravenous cyclophosphamide 500 mg for 6 months. At the end of 6 months, azathioprine (2 mg/kg/d) was started and angiotensin-converting inhibitors and angiotensin receptor blockers were continued. After 18 months of follow-up, the proteinuria was 0.2 g/day, RBCs in urine were absent, and serum creatinine was 1.2 mg/dl.

Discussion

At first presentation, the patient had respiratory symptoms, joint pains, subcutaneous nodules, nasal polyp, raised absolute eosinophil count, and MPO–pANCA positive. All pointed to the diagnosis of Churg-Strauss syndrome. At second presentation, nephrotic syndrome and the subsequent kidney biopsy suggested the diagnosis of membranous nephropathy. The RBC casts in urine, renal impairment, raised absolute eosinophil count, cellular crescent on kidney biopsy, and PANCA-MPO positive suggested the diagnosis of Churg-Strauss syndrome. In English literature, not many reports of membranous nephropathy associated with Churg-Strauss syndrome were available, and there was none from India. In the present patient at second presentation, it was concurrent occurrence of necrotizing crescentic glomerulonephritis superimposed on membranous nephropathy. In the largest series[1] of 14 patients with both pANCA and cANCA associated necrotizing and crescentic glomerulonephritis and membranous nephropathy, MPO-pANCA positivity was present in four patients and pANCA was positive in three more patients. End stage renal disease (ESRD) was the outcome in three of the seven patients. Hanamura et al,[2] reported six patients of MPO positivity on ELISA (ANCA not reported) in patients of membranous nephropathy. Out of them, four patients deteriorated to ESRD. Yu et al,[3] reported both pANCA and cANCA positivity along with only MPO positivity in four patients of membranous nephropathy. Three of these patients reached ESRD. In addition, there were six reports[456789] of eight patients with MPO-pANCA positivity. Only one of these six patients reached ESRD. A recent report[10] presented the coexistence of MPO-pANCA-associated glomerulonephritis and anti-phospholipase A2 receptor antibody positive membranous nephropathy. It has been postulated[2] that in some patients of ANCA-associated glomerulonephritis, MPO may serve as an antigen and form immune complexes to develop membranous nephropathy-like lesions.
  10 in total

1.  Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases.

Authors:  K M Dwyer; J W Agar; P A Hill; B F Murphy
Journal:  Clin Nephrol       Date:  2001-11       Impact factor: 0.975

2.  Membranous glomerulopathy induced by myeloperoxidase-anti-neutrophil cytoplasmic antibody-related crescentic glomerulonephritis.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Tetsuo Tagami; Naoki Sawa; Junichi Hoshino; Hideyuki Katori; Fumi Takemoto; Shigeko Hara; Kumi Aita; Shigeo Hara; Kenmei Takaichi
Journal:  Intern Med       Date:  2005-08       Impact factor: 1.271

Review 3.  Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases.

Authors:  W Y Tse; A J Howie; D Adu; C O Savage; N T Richards; D C Wheeler; J Michael
Journal:  Nephrol Dial Transplant       Date:  1997-05       Impact factor: 5.992

4.  Myeloperoxidase antineutrophil cytoplasmic antibody-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy.

Authors:  Y Taniguchi; N Yorioka; J Kumagai; T Ito; M Yamakido; T Taguchi
Journal:  Clin Nephrol       Date:  1999-10       Impact factor: 0.975

5.  Detection of myeloperoxidase in membranous nephropathy-like deposits in patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Authors:  Kikuno Hanamura; Akihiro Tojo; Satoshi Kinugasa; Kensuke Asaba; Maristela Lika Onozato; Hiroshi Uozaki; Masashi Fukayama; Toshiro Fujita
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

6.  Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission.

Authors:  K Kanahara; N Yorioka; C Nakamura; Y Kyuden; S Ogata; T Taguchi; M Yamakido
Journal:  Intern Med       Date:  1997-11       Impact factor: 1.271

7.  Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.

Authors:  Feng Yu; Min Chen; Su-Xia Wang; Wan-Zhong Zou; Ming-Hui Zhao; Hai-Yan Wang
Journal:  Nephrology (Carlton)       Date:  2007-02       Impact factor: 2.506

8.  Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.

Authors:  Samih H Nasr; Samar M Said; Anthony M Valeri; Michael B Stokes; Naveed N Masani; Vivette D D'Agati; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

9.  Membranous glomerulonephritis with superimposed ANCA-associated vasculitis: another case report.

Authors:  Antonio Granata; Fulvio Floccari
Journal:  NDT Plus       Date:  2010-11-22

10.  Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A(2) receptor antibody-positive membranous nephropathy.

Authors:  Sheena Surindran; Rivka Ayalon; Nazia Hasan; Laurence H Beck; David J Salant; Laura Barisoni; Edward Y Skolnik; Lada Beara-Lasic
Journal:  Clin Kidney J       Date:  2012-03-09
  10 in total
  2 in total

1.  ANCA-Negative Vasculitis in Eosinophilic Granulomatosis with Polyangiitis Complicated with Membranous Nephropathy: A Case Report and Brief Literature Review.

Authors:  Eri Kasama; Jun Ino; Fumika Iemura; Saeko Kumon; Mio Kodama; Keitaro Sato; Hitoshi Eizumi; Kosaku Nitta; Junichi Hoshino
Journal:  Case Rep Nephrol       Date:  2022-05-06

2.  Membranous Nephropathy With MPO-ANCA-Associated Crescentic GN.

Authors:  Kamal Kanodia; Aruna Vanikar; Rashmi Patel; Kamlesh Suthar; Lovelesh Nigam; Vivek Kute; Hargovind Trivedi
Journal:  Nephrourol Mon       Date:  2014-11-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.